Evidence map›Paper›PMID 37152764›Full record

ArticleiScience2023

Timing and implications for immune response to vaccine in SARS-CoV-2 breakthrough infections.

Stefania Arsuffi, Emanuele Sansone, Emanuele Focà, Samuele Storti, Teresa Diaferia, Carlo Bonfanti, Luigina Terlenghi, Arnaldo Caruso, Emma Sala, Francesco Castelli and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Stefania ArsuffiUnit of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili Hospital, Brescia, Italy.
Emanuele SansoneDepartment of Occupational Health and Industrial Hygiene, University of Brescia and ASST Spedali Civili Hospital, Brescia, Italy.
Emanuele FocàUnit of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili Hospital, Brescia, Italy.
Samuele StortiUnit of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili Hospital, Brescia, Italy.
Teresa DiaferiaDepartment of Occupational Health and Industrial Hygiene, University of Brescia and ASST Spedali Civili Hospital, Brescia, Italy.
Carlo BonfantiMicrobiology Department, University of Brescia and ASST Spedali Civili Hospital, Brescia, Italy.
Luigina TerlenghiMicrobiology Department, University of Brescia and ASST Spedali Civili Hospital, Brescia, Italy.
Arnaldo CarusoMicrobiology Department, University of Brescia and ASST Spedali Civili Hospital, Brescia, Italy.
Emma SalaDepartment of Occupational Health and Industrial Hygiene, University of Brescia and ASST Spedali Civili Hospital, Brescia, Italy.
Francesco CastelliUnit of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili Hospital, Brescia, Italy.
Giuseppe De PalmaDepartment of Occupational Health and Industrial Hygiene, University of Brescia and ASST Spedali Civili Hospital, Brescia, Italy.
Eugenia Quiros-RoldanUnit of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili Hospital, Brescia, Italy.
University of Brescia · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

COVID-19 vaccines elicit a strong anti-S antibodies response. We aim to describe antibody titers in peri-vaccination SARS-CoV-2 infections. This is a retrospective longitudinal single-cohort study. Serological tests were performed at the time of the first SARS-CoV-2 vaccine dose (T0) and 60 (T1), 120 (T2), and 240 (T3) days after. The study included 4,682 subjects. Group A had the infection without an anti-S Ig response. Group B and C seroconverted for anti-N Ig between T0 and T1 and between T1 and T2, respectively. Group D was persistently anti-N Ig negative. Group B showed an initial sub-optimal response, reaching the highest titer at T3. Those who received the second dose 120 days after the infection had higher titers compared to those who received it 21 days after the first dose. The immune response depends on the number and the timing of vaccine doses, highlighting the need for a more personalized approach to vaccination.

Indexed as

Health sciencesImmune responseImmunologyVirology

Identifiers

PMID37152764
PMCPMC10122568
OpenAlexW4366747956

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.